RALEIGH, N.C., Nov. 13, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that it won the 2012 US Clinical Researcher of the Year's "Clinical Company of the Year" award as well as several individual honors at the competition's finals ceremony held recently in Cary, NC.
Organized by the PharmaTimes, the event named PRA "Clinical Company of the Year" based on the total points earned by its employees' performances in individual competitions. Four PRA staff members took home 1st and 3rd place prizes in the New Clinical Research Associate, Project Manager and Senior Clinical Research Associate categories. They competed with more than 200 other contestants in a rigorous three-phase process that tested their skills in risk-based monitoring and virtual teamwork.
"This competition is a great forum for our employees to showcase their unique talents within our industry," said Susan Romberg, PRA's Vice President of Clinical Operations. "We are very proud to have participated for our second straight year in this competition."
In the New Clinical Research Associate category, PRA's Elizabeth Watson and Jon Faber won 1st and 3rd places, respectively. Hillary Denny took 1st place in the Senior Clinical Research Associate competition, while Michael Long received 3rd in the Project Manager category. In addition, PRA had seven other finalists compete in the event.
Ms. Watson said, "This is such a great experience because I get to interact with some of the best professionals in the industry. The camaraderie and support from PRA throughout this process has been incredible. I look forward to being able to compete again next year."
PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.
We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.